Flow cytometry–triggered genomic testing and automation reduced turnaround times for AML diagnostics, enhancing personalized therapy and patient care. The initiative involved clinician education, a ...

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Qlucore, listed on Nasdaq First North, announces the launch of a new Qlucore Insights test (Research Use Only) specifically developed for Acute Myeloid Leukemia (AML). The software-based test delivers ...